OncLive
OncLive, Plainsboro, NJ. 16K likes. OncLive covers every angle of your oncology practice, from new technology to treatment advances to important regulatory decisions
Related Articles
Five Under 5: Top Oncology Videos for the Week of 5/4
The top 5 OncLive videos of the week cover insights in myelodysplastic syndrome, lung cancer, hepatocellular carcinoma, colorectal cancer, and ovarian cancer.
Nadofaragene Firadenovec Yields High 3-Month CR Rates in High-Risk BCG-Unresponsive NMIBC With CIS
Nadofaragene firadenovec was safe and produced high CR rates at 3 months in Japanese patients with high-risk BCG-unresponsive NMIBC and CIS.
Oncodetect Test Is Now Available for MRD Detection in Solid Tumors
The Oncodetect test is now available for use in molecular residual disease detection in patients with solid tumors.
The OncFive: Top Oncology Articles for the Week of 5/4
A doublet is approved for KRAS-mutated ovarian cancer, T-DXd followed by THP improves pCR rates in HER2+ breast cancer, and more from OncLive.
Salvage ASCT Shows No Long-Term PFS or OS Benefit in Relapsed Myeloma
Salvage transplant was not associated with long-term survival benefits in relapsed/refractory multiple myeloma.
Sacituzumab Govitecan Plus Pembrolizumab Improves PFS in PD-L1–Positive mTNBC
The combination of sacituzumab govitecan and pembrolizumab improved PFS vs pembrolizumab plus chemotherapy in PD-L1–positive mTNBC.
T-DXd/Pertuzumab Yields PFS Benefit vs THP in HER2+ Metastatic Breast Cancer
Frontline T-DXd plus pertuzumab led to statistically significant and clinically meaningful PFS improvements vs THP in HER2+ metastatic breast cancer.
Treatment Strategies in 2L R/R FL: When to Treat vs Observe in Relapsed Disease
Panelists discuss how the treatment approach for relapsed or progressive follicular lymphoma (R/R FL) in the second-line (2L) setting is evolving, focusing on the role…
National Fellows Forum: Gastrointestinal Cancer
Take this survey powered by surveymonkey.com. Create your own surveys for free.
THE001 Receives Orphan Drug Designation for Soft Tissue Sarcoma
THE001, a doxorubicin-encapsulating thermosensitive liposome therapy, has been granted FDA orphan drug designation for soft tissue sarcoma.